TrialInternational journal of clinical oncology2019

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).

Shin Fujisawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.